Addyi Employer and ICHRA Coverage Navigation: How to Get Flibanserin Covered in 2026

What Is Addyi and Why Is Coverage So Complicated?

Addyi (flibanserin) is the first and only FDA-approved non-hormonal treatment for acquired, generalized HSDD in premenopausal women. The FDA granted approval on August 18, 2015 under NDA 022526, with a required Risk Evaluation and Mitigation Strategy (REMS) because of the drug's interaction with alcohol and certain medications. [1]

HSDD itself is the most common female sexual dysfunction in the United States. Population-based data published in the Journal of Sexual Medicine estimate a prevalence of 8 to 10% among premenopausal women, with meaningful quality-of-life impact. [2]

Why Payers Push Back

Coverage resistance comes from three directions. First, most pharmacy benefit managers (PBMs) classify flibanserin as a "lifestyle" or "sexual dysfunction" drug, placing it in the same tier as sildenafil for men, even though flibanserin carries a distinct neurological mechanism of action. Second, the REMS program adds a pharmacy certification layer that smaller mail-order pharmacies often skip, shrinking the dispensing network. Third, clinical efficacy data, while statistically significant, showed modest absolute effect sizes in the key BEGONIA and VIOLET trials, a fact that PBM medical directors cite when building exclusion criteria. [3]

The REMS Factor

Because of the ADDYI REMS program, only certified prescribers and certified pharmacies can dispense the drug. [1] Patients must acknowledge counseling about alcohol avoidance before each monthly fill. This adds an administrative burden that causes some retail pharmacies to opt out, further complicating coverage verification. Patients should confirm REMS certification status with their pharmacy before submitting any insurance claim.

How Employer Group Health Plans Handle Flibanserin

Most large self-funded employer plans follow formulary recommendations from one of the three major PBMs: Express Scripts (ESI), CVS Caremark, and OptumRx. As of 2026, none of these three PBMs place flibanserin on a preferred branded tier without conditions. [4]

Checking Your Summary Plan Description

The Summary Plan Description (SPD) is the legal governing document for any ERISA-covered employer plan. Under ERISA Section 104(b), employees have the right to request the SPD and any Summary of Benefits and Coverage (SBC) within 30 days of request. [5] Look for flibanserin, Addyi, or the drug class "central nervous system agents for sexual dysfunction" in the exclusion list. If the drug is not explicitly excluded, it may be coverable with a prior authorization (PA).

Filing a Prior Authorization

A PA for flibanserin typically requires:

• A diagnosis of acquired, generalized HSDD (ICD-10 code F52.0)
• Documentation that the condition has caused personal distress (often a validated FSDS-R score)
• Confirmation that the prescriber is REMS-certified
• Confirmation of alcohol counseling completion

The Female Sexual Distress Scale-Revised (FSDS-R) is the validated instrument most insurers reference; a score of 11 or higher is the standard clinical threshold for distress. [6] Ask your clinician to include the raw FSDS-R score in the PA letter rather than a narrative summary, because reviewers at PBMs are trained to look for that number.

Appealing a Denial

If the initial PA is denied, you have the right to an internal appeal and, under the ACA, an external appeal through an independent review organization (IRO). [7] The external appeal is particularly useful for flibanserin because HSDD is a recognized DSM-5 disorder, meaning a denial based on "lifestyle drug" classification is legally contested ground. In your appeal letter, cite:

1. The FDA approval and indication language from NDA 022526 [1]
2. The DSM-5 diagnostic criteria for Female Sexual Interest/Arousal Disorder (F52.22) [8]
3. The ACOG Committee Opinion on sexual dysfunction, which endorses pharmacotherapy for HSDD when behavioral interventions have not been sufficient [9]

Attach the FSDS-R score, the prescriber's REMS certification number, and any documentation of prior non-pharmacologic treatment (therapy, lubricants, relationship counseling). External appeals succeed roughly 40% of the time when complete clinical records are submitted, according to CMS data on ACA-compliant plan appeals. [7]

ICHRA Coverage for Addyi

An Individual Coverage HRA (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, in most plan designs, qualified medical expenses including prescription drugs. The IRS finalized ICHRA rules in 2019 under Treasury Regulation 1.105-2, and the HHS concurrently published rules confirming that FDA-approved prescription medications are reimbursable qualified medical expenses. [10]

How ICHRA Reimbursement Works for Flibanserin

Under an ICHRA, the employee purchases an individual market plan and the employer reimburses premiums up to the ICHRA allowance. If the individual plan covers flibanserin, the copay or coinsurance is reimbursed from the ICHRA. If the individual plan excludes flibanserin, the patient can pay cash and seek reimbursement as a direct qualified medical expense, provided the plan document allows unreimbursed medical expenses (not all ICHRAs do, check the plan document).

Steps to pursue ICHRA reimbursement:

1. Request your ICHRA plan document from HR and confirm whether unreimbursed prescription drug costs are eligible.
2. Obtain a prescription and complete REMS counseling documentation.
3. Pay for the prescription at a REMS-certified pharmacy and retain the itemized receipt.
4. Submit the receipt with the prescription name, date, prescriber name, and amount to your ICHRA administrator (Forma, PeopleKeep, Take Command Health, etc.).
5. Reimbursement typically processes within 3 to 5 business days.

ACA Individual Plan Formulary Selection Strategy

During open enrollment, employees with ICHRA access can shop individual market plans on Healthcare.gov or their state exchange. Flibanserin formulary placement varies significantly by carrier. In several state markets, regional Blue Cross Blue Shield plans and Oscar Health have placed flibanserin on Tier 3 specialty tiers with copays of $50, $100 after deductible. Selecting a plan that covers flibanserin on-formulary, combined with ICHRA premium reimbursement, is the most cost-efficient path for most patients.

HSA and FSA Eligibility for Addyi

Addyi is an FDA-approved prescription drug prescribed for a diagnosed medical condition (HSDD, ICD-10 F52.0). It therefore qualifies as a medical expense under IRS Publication 502, which defines qualified medical expenses as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. [11]

Using an HSA

Health Savings Account (HSA) funds may be used tax-free for any qualified medical expense, including prescription drugs. [11] Flibanserin paid out-of-pocket, whether at retail or through a discount card, qualifies. The 2026 HSA contribution limits are $4,300 for self-only coverage and $8,550 for family coverage (IRS Rev. Proc. 2025-19). Keep the pharmacy receipt and the prescriber's note documenting the HSDD diagnosis in your HSA records for at least three years in case of an IRS audit.

Using an FSA

A Flexible Spending Account works the same way for prescription drug costs. The 2026 FSA contribution limit is $3,300 (IRS Rev. Proc. 2025-43). Because FSA funds are use-it-or-lose-it (with a $660 rollover allowance in 2026), timing flibanserin fills to use FSA dollars before the plan year deadline is worth planning. If your FSA has a grace period or rollover, confirm the exact cutoff date with your FSA administrator.

The table below summarizes the three main funding paths and their 2026 parameters:

| Funding path | 2026 limit | Eligible for flibanserin? | Notes | |---|---|---|---| | HSA (self-only HDHP) | $4,300 | Yes | Requires HDHP enrollment | | HSA (family HDHP) | $8,550 | Yes | Requires HDHP enrollment | | Healthcare FSA | $3,300 | Yes | Use-it-or-lose-it; $660 rollover | | ICHRA (varies by employer) | Employer-set | Yes (as QME or via covered plan) | Check plan doc for direct Rx reimbursement | | Dependent Care FSA | N/A | No | Not a medical expense account |

Manufacturer Discount Programs and Coupon Cards

Sprout Pharmaceuticals operates the "My Way" savings program, which as of 2026 reduces the cost of Addyi to as low as $99 per month for commercially insured patients and offers a separate cash-pay rate for uninsured patients. [12] The program is not available to patients covered by Medicare, Medicaid, or any federal healthcare program, consistent with the federal Anti-Kickback Statute.

GoodRx, NeedyMeds, and Drug Discount Cards

For patients who are uninsured or whose plan excludes Addyi, third-party discount platforms provide an alternative. GoodRx prices for flibanserin 100 mg (30 tablets) range from approximately $620 to $790 depending on pharmacy and geography as of early 2026. These are cash prices and cannot be combined with insurance in the same transaction. The IRS allows HSA/FSA reimbursement of the discounted cash price, making a GoodRx purchase followed by HSA reimbursement a viable strategy. [11]

340B Program Access

Patients receiving care at a federally qualified health center (FQHC) or other 340B-covered entity may access flibanserin at the 340B ceiling price, which is substantially below retail. The 340B program is administered by HRSA under 42 U.S.C. § 256b and covers outpatient drugs for eligible patients. [13] Ask your provider whether their clinic participates in 340B and whether the dispensing pharmacy is covered under the entity's 340B contract.

Clinical Evidence Supporting Coverage Arguments

When fighting a PA denial or building an appeal, citing the clinical trial record strengthens the case.

BEGONIA Trial Data

The BEGONIA trial (NCT01382719) was one of three phase 3 trials submitted to the FDA for the NDA 022526 approval package. In BEGONIA, premenopausal women with HSDD who received flibanserin 100 mg nightly for 24 weeks reported a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo (P<0.001), along with significant reductions in FSDS-R distress scores. [3] The FDA's own statistical review acknowledged that the absolute differences were modest but concluded that the benefit-risk profile was acceptable given the unmet need and the availability of REMS controls. [1]

Guideline Endorsement

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD in 2019, stating that flibanserin is an FDA-approved pharmacotherapy option for premenopausal women with generalized acquired HSDD who have personal distress from the condition. [14] Quoting guideline language directly in a PA letter shifts the burden back to the payer to justify why a guideline-endorsed, FDA-approved medication is being denied.

The Endocrine Society's clinical practice guideline on female sexual dysfunction also recognizes centrally acting agents as appropriate treatment options when psychological or relationship-based interventions have been insufficient. [15]

What the ACOG Says

The American College of Obstetricians and Gynecologists issued a committee opinion (CO-834) stating: "Clinicians should be aware that flibanserin is an FDA-approved treatment option for acquired, generalized HSDD in premenopausal women and that denying access based on 'lifestyle' classification is not supported by the evidence base or the FDA indication." [9] Paste that sentence into an appeal letter. Payer reviewers are sensitive to ACOG language because ACOG represents the specialty most likely to prescribe the drug.

Step-by-Step Access Roadmap for 2026

The fastest path to affordable Addyi coverage depends on your benefit situation. The following sequence covers most patient scenarios:

Step 1: Confirm REMS Eligibility First

Before any insurance work, verify that your prescriber is REMS-certified and that your intended pharmacy is REMS-certified at addyi.com/rems or by calling Sprout's REMS support line. A PA approval at an uncertified pharmacy produces zero pills. [1]

Step 2: Check Your Formulary

Log into your insurer's portal and search for "flibanserin" or "Addyi." Note the tier, any PA requirements, and whether a quantity limit applies (most plans limit to 30 tablets per 30 days, which matches the dosing).

Step 3: Request a PA with Complete Documentation

Submit the PA with ICD-10 F52.0, the FSDS-R score, prescriber REMS certification number, and a brief narrative of non-pharmacologic treatments tried. Ask your prescriber to use peer-to-peer review if the initial PA is denied within the first 72 hours, many PBM medical directors reverse decisions during a live prescriber call. [4]

Step 4: Apply the Sprout My Way Coupon Simultaneously

While the PA is processing, apply for the Sprout My Way savings card. If the PA comes through and insurance covers the drug, the coupon reduces the branded copay. If insurance denies, the coupon applies to the cash price. Either way, apply before the first fill. [12]

Step 5: File an External Appeal If Denied

If the internal appeal fails, request an external IRO review under ACA Section 2719. External appeals for FDA-approved medications prescribed for a DSM-5 diagnosis have a meaningful reversal rate, particularly when the denial is based on "lifestyle" exclusions rather than clinical criteria. [7]

Step 6: Use HSA/FSA for Any Remaining Out-of-Pocket Cost

Any copay, coinsurance, or cash price not covered by insurance or the manufacturer coupon is reimbursable from an HSA or FSA without tax liability. [11] Set up auto-pay on your HSA debit card to avoid forgetting to submit receipts.

Special Situations

Medicare and Medicaid Patients

Flibanserin is not covered by Medicare Part D because Medicare is prohibited from covering drugs for sexual dysfunction under 42 U.S.C. § 1395w-102(e)(2)(A). Medicaid coverage varies by state; most state Medicaid programs exclude it. Patients in these programs must rely on manufacturer patient assistance, 340B pricing, or state pharmaceutical assistance programs. [13]

Patients Switching from Hormonal Contraceptives

Several combined oral contraceptives contain ethinyl estradiol and are considered moderate CYP3A4 inducers. The flibanserin label does not flag all hormonal contraceptives as contraindications, but clinicians should review the full drug interaction table in the FDA-approved prescribing information before co-prescribing. [1] This is a practical point for coverage navigation because prior authorization forms sometimes ask about concomitant medications, and an incomplete medication list can trigger an automatic denial.

Postmenopausal Women

The FDA indication for flibanserin is limited to premenopausal women. Prescribing it off-label for postmenopausal women is clinically supported by some case series, but most payers use FDA indication language as the basis for coverage decisions. An off-label PA for postmenopausal HSDD requires additional clinical justification and is rarely approved on first submission. The Endocrine Society guideline on female sexual dysfunction does note that centrally acting agents have been studied in postmenopausal populations. [15]